RORγt Inverse agonist 10

Modify Date: 2025-08-21 17:02:26

RORγt Inverse agonist 10 Structure
RORγt Inverse agonist 10 structure
Common Name RORγt Inverse agonist 10
CAS Number 2413986-35-1 Molecular Weight 572.50
Density N/A Boiling Point N/A
Molecular Formula C25H26F6N6O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of RORγt Inverse agonist 10


RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC50 of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R[1]

 Names

Name RORγt Inverse agonist 10

 RORγt Inverse agonist 10 Biological Activity

Description RORγt Inverse agonist 10 is a potent and orally bioavailable RORγt (retinoic acid receptor-related orphan nuclear receptor gamma t) inverse agonist, with an IC50 of 51 nM. RORγt is a major transcription factor of genes related to psoriasis pathogenesis such as IL-17A, IL-22, and IL-23R[1]
Related Catalog
Target

RORγt:51 nM (IC50)

In Vitro RORγt Inverse agonist 10 has a good liver microsome stability (human CLint=0.010 mL/min/mg, mouse CLint=0.030 mL/min/mg)[1]. RORγt Inverse agonist 10 suppresses the IL-17A production in a dose-dependent manner with an IC50 of 130 nM in a human whole-blood assay[1].
In Vivo RORγt Inverse agonist 10 (3-100 mg/kg; p.o.) shows robust and dose-dependent inhibitory effect on the IL-17A production in mouse IL-18/23-induced cytokine expression model[1]. RORγt Inverse agonist 10 (1.145 mg/kg; p.o.) shows a high AUC of 15000 nM*h and t1/2 of 3.6 hours[1]. Animal Model: C57/BL6 male mice, mouse IL-18/23-induced cytokine expression model[1] Dosage: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg Administration: Oral administration Result: Significantly inhibited the IL-17A production in a dose-dependent manner. Animal Model: Mice[1] Dosage: 1.145 mg/kg (Pharmacokinetic Analysis) Administration: Oral administration Result: AUC=15000 nM*h, t1/2=3.6 hours.
References

[1]. Ryota Nakajima, et al. Discovery of [1,2,4]Triazolo[1,5- a]pyridine Derivatives as Potent and Orally Bioavailable RORγt Inverse Agonists. ACS Med Chem Lett. 2020 Feb 27;11(4):528-534.

 Chemical & Physical Properties

Molecular Formula C25H26F6N6O3
Molecular Weight 572.50
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here

Get all suppliers and price by the below link:

RORγt Inverse agonist 10 suppliers

RORγt Inverse agonist 10 price